Last reviewed · How we verify
Humira biosimilars
19 approved
0 filed
13 Phase 3
All key patents expired
About Humira
Humira (ADALIMUMAB) — originally marketed by AbbVie. Class: TNF blocker. Target: Tumor Necrosis Factor-alpha (TNF-alpha). Area: Oncology. First approved 2002-01-01.
Approved biosimilars (19)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Abrilada | AbbVie | marketed | 2002-01-01 | |
| YUFLYMA | CELLTRION | marketed | ||
| Adalimumab with methotrexate | Pfizer | marketed | ||
| SIMLANDI | ALVOTECH USA INC | marketed | ||
| HADLIMA | SAMSUNG BIOEPIS CO LTD | marketed | ||
| adalimumab, plus prednisone | Fondazione IRCCS Policlinico San Matteo di Pavia | marketed | ||
| Adalimumab (ADA) | JHSPH Center for Clinical Trials | marketed | ||
| Adalimumab treatment arm | Medical University of Vienna | marketed | ||
| Adalimumab, etanercept, infliximab | University of Padova | marketed | ||
| Adalimumab and its biosimilars | Hanyang University Seoul Hospital | marketed | ||
| HULIO | MYLAN PHARMS INC | marketed | ||
| YUSIMRY | COHERUS BIOSCIENCES INC | marketed | ||
| Adalimumab plus different doses of oral glucocorticosteroid | Peking Union Medical College Hospital | marketed | ||
| CYLTEZO | BOEHRINGER INGELHEIM | marketed | ||
| Adalimumab (Humira) | Tufts Medical Center | marketed | ||
| HYRIMOZ | SANDOZ INC | marketed | ||
| SB5 (Adalimumab Biosimilar) | Samsung Bioepis Co., Ltd. | marketed | ||
| IDACIO | FRESENIUS KABI USA | marketed | ||
| Adalimumab Ab | Qilu Hospital of Shandong University | marketed |
Filed biosimilars under regulatory review (0)
Phase 3 biosimilars (13)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Adalimumab - GP2017 | Sandoz | phase 3 | ||
| adalimumab (D2E7) | Abbott | phase 3 | ||
| MYL-1401A (Adalimumab) | Mylan Inc. | phase 3 | ||
| CT-P17 SC AI (adalimumab) | Celltrion | phase 3 | ||
| Adalimumab+Methotrexate | Hospital San Carlos, Madrid | phase 3 | ||
| Adalimumab subcutaneous injection | Biocad | phase 3 | ||
| Adalimumab biosimilar | Alvotech Swiss AG | phase 3 | ||
| Adalimumab - US licensed Humira | Sandoz | phase 3 | ||
| Adalimumab Every Week | Innovaderm Research Inc. | phase 3 | ||
| Adalimumab (40 mg) | Janssen Scientific Affairs, LLC | phase 3 | ||
| GP2017 Adalimumab | Sandoz | phase 3 | ||
| Adalimumab every other week | Innovaderm Research Inc. | phase 3 | ||
| Adalimumab originator | Alvotech Swiss AG | phase 3 |
Originator patent timeline
Active patents (0)
Expired patents (0)
Subscribe to biosimilar updates
Every regulatory action on Humira or any of its biosimilars: